EichorEICHOR
Condition: Breast Cancer Her2 Positive Metastatic Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Breast Cancer Her2 Positive Metastatic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast
Phase 2 · 2 location(s) · University of Washington · NCT06179303Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Brea
Phase 2/Phase 3 · 9 location(s) · Shanghai Pharmaceuticals Holding Co., Ltd · NCT05744687Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormon
Phase N/A · 24 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06805812Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
Phase 2 · 27 location(s) · SOLTI Breast Cancer Research Group · NCT07371585Basket Study for Oligo-metastatic Breast Cancer
Phase 2 · 1 location(s) · The Netherlands Cancer Institute · NCT05982678Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recur
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT05838066Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
Phase 3 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT04646759Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
NA · 1 location(s) · University of Miami · NCT05959291A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07612891A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent
Phase 3 · 25 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07003074Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Phase 1/Phase 2 · 3 location(s) · Icahn School of Medicine at Mount Sinai · NCT05095207A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Phase 3 · 40 location(s) · AstraZeneca · NCT07205822Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NA · 1 location(s) · Brigham and Women's Hospital · NCT04030507Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07258108Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
Phase 1/Phase 2 · 2 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04923542Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07486089Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
Phase 2 · 1 location(s) · University of California, San Diego · NCT07227233A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other
Phase 1 · 7 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05461768A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Adva
Phase 2 · 1 location(s) · Shanghai Henlius Biotech · NCT06832202DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
Phase N/A · 1 location(s) · Mayo Clinic · NCT06388122ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Phase 2 · 1 location(s) · Laura Huppert, MD, BA · NCT06224673Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
Phase 2 · 1 location(s) · UNICANCER · NCT06450314Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Phase 3 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06278870A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Phase 1 · 18 location(s) · Totus Medicines · NCT05683418Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastat
NA · 1 location(s) · Washington University School of Medicine · NCT04968964DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Phase 2 · 3 location(s) · Nancy Lin, MD · NCT06176261SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nerv
NA · 1 location(s) · Royal College of Surgeons, Ireland · NCT07503717Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated
Phase 2 · 2 location(s) · Sunnybrook Health Sciences Centre · NCT06016387A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Phase 2/Phase 3 · 1 location(s) · Shanghai Henlius Biotech · NCT07294508OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Phase 3 · 233 location(s) · Olema Pharmaceuticals, Inc. · NCT06016738
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.